Skip to main content
logo
Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
5.16
-0.06 (-1.15%)
At close: Jan 2, 2026, 4:00 PM EST
5.19
+0.03 (0.57%)
Pre-market: Jan 5, 2026, 8:00 AM EST

Radiopharm Theranostics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
3.630.30.29--
Other Revenue
8.881.665.92--
Revenue
12.511.966.21--
Revenue Growth (YoY)
538.86%-68.46%---
Cost of Revenue
31.1121.6119.537.49-
Gross Profit
-18.6-19.65-13.32-7.49-
Selling, General & Admin
14.6413.0412.237.640.3
Operating Expenses
16.5315.6815.2712.441.16
Operating Income
-35.13-35.33-28.59-19.93-1.16
Interest Expense
-0.07-0.64-0.09-9.35-
Interest & Investment Income
0.890.050.150.01-
Currency Exchange Gain (Loss)
0.140.09-0.26-1.11-0
EBT Excluding Unusual Items
-34.17-35.83-28.79-30.38-1.16
Gain (Loss) on Sale of Assets
--1.69---
Asset Writedown
--1.48-3.1--
Other Unusual Items
-4.07-8.86-2.68--
Pretax Income
-38.24-47.85-34.57-30.38-1.16
Income Tax Expense
0.10.10.040.04-
Net Income
-38.34-47.95-34.61-30.42-1.16
Net Income to Common
-38.34-47.95-34.61-30.42-1.16
Shares Outstanding (Basic)
2,081386306181-
Shares Outstanding (Diluted)
2,081386306181-
Shares Change (YoY)
438.49%26.36%68.74%--
EPS (Basic)
-0.02-0.12-0.11-0.17-
EPS (Diluted)
-0.02-0.12-0.11-0.17-
Free Cash Flow
-36.65-22.98-23.25-9.91-0.08
Free Cash Flow Per Share
-0.02-0.06-0.08-0.06-
Gross Margin
-148.63%--214.52%--
Operating Margin
-280.77%-1803.82%-460.41%--
Profit Margin
-306.44%-2448.23%-557.36%--
Free Cash Flow Margin
-292.88%-1173.12%-374.36%--
EBITDA
-32.53-32.2-25.29-16.94-
EBITDA Margin
-260.03%----
D&A For EBITDA
2.63.133.32.98-
EBIT
-35.13-35.33-28.59-19.93-1.16
EBIT Margin
-280.77%----
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q